Researchers are targeting autoimmune epilepsy and chronic inflammatory demyelinating polyneuropathy.
By Karen MacPhail and Gabriela Espinoza, MD
July 25th, 2017
As many as one billion people worldwide suffer from more than 600 neurological disorders, according to the World Health Organization and University of California, San Francisco, respectively. Of that number, it is estimated that 6.8 million people die each year from neurological disorders ranging from epilepsy to Alzheimer’s disease.
Neurological disorders affect the central nervous systems or the peripheral nervous systems and can impair the brain, spinal cord, peripheral nerve or neuromuscular function.
The CSL Behring Professor Heimburger Award is helping to ensure young researchers around the world have the opportunity to bring their innovative ideas to the forefront.
October 17, 2016
We are seeing some exciting research as CSL Behring delivers on our promise to advance research and innovation through grants such as the Heimburger Award.
This is particularly important for young researchers working in clinics who often don’t have time to raise money for their research. Adding to the challenge is the fact that government funding of orphan disease research is often difficult to obtain.
It’s difficult for most of us to fully appreciate what it’s like to have a rare disease caused by a deficient or defective protein. Traditionally, patients with certain types of protein deficiency or defect had no option other than to be intravenously injected two to three times per week with conventional therapies.
Teamwork: bringing rIX-FP to patients is a culmination of several years of work across the entire global organization. Seen here are members of CSL Behring’s rIX-FP Clinical Research and Development team in King of Prussia, Pa., U.S.
While frequent injections (prophylaxis) may prevent the onset of symptoms in most instances, this approach is a burden for patients who lead busy lives. It is also the main reason that routine prophylaxis is often delayed in young children. In addition, some symptoms can cause progressive and in certain patients debilitating damage.
Today we proudly mark CSL’s 100th anniversary, a milestone that is a testament to our values, science, people, and the patients we serve. For the past 100 years our vision, focus and agility have remained steadfast, enabling us to accomplish this feat. We have a rich heritage with an even brighter future. In many ways, we’re just getting started.
As a tangible expression of our values in action, and as a way of celebrating the CSL Centenary, we are establishing a $25 million R&D Fellowship program for early stage and translational research. The R&D Fellowship reflects the promise we made a century ago to save lives and protect people’s health. Continue reading →
This is encouraging news for people with rare and serious diseases.
February 4, 2015
By Val Romberg
The future of protein therapeutics is bright and holds great promise for the development of new medicines that save lives by preventing or treating serious illness. Our forte at CSL Behring is the collection and purification of proteins from human plasma, which is the liquid portion of blood, to create lifesaving medicines. Continue reading →
Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring. This site is not intended as a forum for discussing CSL Behring or other companies' products. Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.